<DOC>
	<DOCNO>NCT01561924</DOCNO>
	<brief_summary>This trial conduct Europe United States America ( USA ) . The aim trial evaluate basal spike TEG® ( Thromboelastography ) ROTEM® ( Thromboelastometry ) profile frequently bleed haemophilia subject inhibitor non-bleeding state .</brief_summary>
	<brief_title>Prediction Efficacy Activated Recombinant Human Factor VII Adult Congenital Haemophilia A B Patients With Inhibitors Use Thromboelastography</brief_title>
	<detailed_description>The TEG parameter : R time ( Reaction Time ) , K time ( K Time ( arbitrary measurement ) ) , ( angle ) , MA ( Maximum Amplitude ) LY30 ( Lysis 30 min MA ) ROTEM parameter : CT ( Clotting Time ) , CFT ( Clot Formation Time ) , ( angle ) , MCF ( Maximum Clot Firmness ) LI60 ( Lysis index 60 min CT )</detailed_description>
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Hemophilia B</mesh_term>
	<mesh_term>Blood Coagulation Disorders</mesh_term>
	<mesh_term>Hemostatic Disorders</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Confirmed diagnosis congenital haemophilia A B FVIII : C clot activity FIX : C clot activity , respectively , less 5 % Presently use activate recombinant human factor VII ( NovoSeven® ) haemostatic agent preventive treatment treatment bleed episodes A documented historical present record presence inhibitor factor VIII IX , respectively A documented history 2 joint bleed episode precede 12 month Subjects must nonbleeding state ( i.e . clinical manifestation active bleeds ) Subjects receive haemostatic treatment bleed episode within last 7 day prior trial Immune tolerance therapy within last 30 day prior trial Clinically relevant coagulation disorder congenital haemophilia A B Thrombocytopenia ( platelet count 60,000 platelets/mcl ) Prophylactic haemostatic treatment within 3 day prior trial</criteria>
	<gender>Male</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>